Follow-up of pathological stage I and IIA supradiaphragmatic Hodgkin's disease primarily treated with radiotherapy. 1982

A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani

One hundred and fifty-five consecutive previously untreated adult patients with supradiaphragmatic pathologic stage IA (71) and IIA (84) Hodgkin's disease treated only with radiotherapy (RT) at the Istituto Nazionale Tumori of Milano from 1970 to 1978 were reviewed. Staging procedures included lymphangiography and laparotomy in all cases. Most patients were irradiated with a conventional cobalt machine. Mantle fields were adopted for 36.8% of cases, mainly at stage I, whereas 63.2% received mantle plus paraaortal irradiation. Doses were above 40 Gy for involved sites and 35-40 Gy for prophylactically irradiated nodes. Minimum and median follow-up were 30 months and 6 years, respectively. All patients achieved complete remission at the end of RT. As of June 1981, 89 of 155 patients (57.5%) were alive and free from progression, 60.6% at stage I, and 54.8% at stage II. Relapses occurred in 54 of 155 cases (35%) after a median free interval of 21 months. Marginal recurrences accounted for 5.8%, true recurrences for 9%, nodal extensions for 8.4%, and extranodal extensions for 11.6%. Males older than 40 years and mediastinal involvement were correlated with higher relapse rates. Salvage treatment consisted of RT alone in 8 patients and chemotherapy plus or minus RT in 44, whereas 2 patients died before a new treatment could start. As of June 1981, 38 of 54 relapsed patients (70.4%) were alive and disease free, whereas 2 were alive with evidence of disease. Actuarial overall survival at 6 years was 90.3% for all cases, 97.1% for stage I, and 84.8% for stage II. Treatment toxicity was analyzed, and problems concerning surgical staging procedures, optimal RT and role of chemotherapy as primary or salvage treatment were discussed.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003037 Cobalt Radioisotopes Unstable isotopes of cobalt that decay or disintegrate emitting radiation. Co atoms with atomic weights of 54-64, except 59, are radioactive cobalt isotopes. Radioisotopes, Cobalt
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
April 1984, Lancet (London, England),
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
September 1989, Clinical oncology (Royal College of Radiologists (Great Britain)),
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
February 2000, American journal of clinical oncology,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
January 1992, International journal of radiation oncology, biology, physics,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
December 1991, Blood reviews,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
July 1999, International journal of radiation oncology, biology, physics,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
October 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
February 2003, Leukemia & lymphoma,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
June 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Banfi, and M Zanini, and R Zucali, and S B Ricci, and A Lattuada, and F Milani, and R Rizzato, and F Volterrani
January 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!